The positive rate of amyloid beta protein, indicating the risk of Alzheimer's disease-causing substance accumulation, was ...

A recent paper published in Nature Medicine sheds light on a remarkable case where Alzheimer's appears to have been medically acquired through the transmission of the amyloid-beta protein. Typically ...

The availability of amyloid-reducing therapies now makes detection of Alzheimer's disease in its early stages critical, ...

With Eisai and Biogen’s Leqembi and Eli Lilly’s Kisunla launching onto the market, the 2024 Clinical Trials of Alzheimer’s ...

Early data suggest Roche’s antibody may safely and quickly remove amyloid plaque for patients with Alzheimer’s disease, though the mid-stage study has been tied to one death. | Early data suggest ...

But poor sleep is both a risk factor for and a symptom of Alzheimer's disease, making it tricky to tease apart cause and ...

In a small early trial using a transcranial magnetic stimulation procedure, scientists were able to target a key brain ...

We asked Dr. Joanne Pike, CEO of the Alzheimer's Association to help explain the challenges and hopes when it comes to this debilitating disease.

Panax ginseng shows highest effectiveness in treating Alzheimer's. Learn more about AVXL's blarcamesine and SAVA's simufilam ...

Acumen, with a strong cash position of $258.9 million, is poised to sustain operations into 2027, boosting investor confidence in their innovative approach to targeting toxic amyloid beta oligomers in ...

Dr Charles Vega believes that primary care will be the chief clinical setting for application of new blood-based biomarkers.

Alzheimer's disease is characterized by a progressive loss of nerve cells leading to a decline in memory and cognition.